According to new research many drugs are approved on the brink of FDA deadlines, and these drugs are more likely to later face regulatory intervention for safety reasons. Drugs fast-tracked by the FDA are more likely to eventually be withdrawn from global markets for safety reasons, undergo manufacturing revisions, or face labeling changes.



Recent comments
29 weeks 4 days ago